The HER2-enriched subtype is ER and PR negative and HER2 positive, and the basal-like subtype is ER and PR negative and HER2 negative (triple-negative breast cancer) [27,28,29]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.